Integration of Diabetes Technology in Clinical Practice.
This article attempts to aid clinicians in using diabetes devices in their clinical practice. It reviews device selection, initiation, and follow-up. It discusses work flow in an office and provides tips on billing. It stresses the need for patient choice, education, and on-going support through downloading and interpretation of data to optimize care. PMID: 31980122 [PubMed - in process]
Antipsychotic medications are a vital part of controlling psychosis in schizophrenic patients. However, when those patients live in nursing facilities, we are obligated by CMS to undertake gradual dose reductions of antipsychotic medication if possible. Sometimes, these efforts are successful and sometimes they fail. Antipsychotic medications have many side effects, including sedation, diabetes, hyperlipidemia, weight gain, motor rigidity, impaired gait, and falls. Monitoring of blood glucose, lipids, and extrapyramidal symptoms is mandatory.
Management of diabetes in post-acute settings needs special considerations. Hypoglycemia in the skilled nursing and rehabilitation facilities can lead to readmissions and complications including falls. Current EHR care-sets may not make a distinction between hospital and post-acute settings regarding diabetes management. The current diabetes management care-set in the EHR of our large healthcare system includes checking the blood sugar QID/AC/HS (before breakfast, lunch and dinner, and bedtime).
Authors: Lee YM, Park SH, Lee DH Abstract OBJECTIVE: The aim of this paper is to propose a new hypothesis for the role of lipophilic chemical mixtures stored in adipose tissue in the development of dementia. Specifically, we present how the dynamics of these chemicals can explain the unexpected findings from the Action for Health in Diabetes (Look AHEAD) study, which failed to show long-term benefits of intentional weight loss on cognition, despite substantial improvements in many known risk factors for dementia. Moreover, we discuss how the role of obesity in the risk of dementia can change depending on the dynami...
Authors: Medeiros MC, Rocha N, Bandeira E, Dantas I, Chaves C, Oliveira M, Bandeira F Abstract Sclerostin (Scl) is an osteoblast-inhibiting glycoprotein that is secreted mainly by osteocytes and is regulated by hormonal changes and skeletal loading. Decreased physical function and high serum Scl concentrations have been reported in chronic renal failure patients but little is known to date about the differences between diabetic and non-diabetic patients on hemodialysis who are susceptible to both sarcopenia and bone fragility. Objective.To determine the prevalence of sarcopenia and its association with serum Scl co...
Publication date: Available online 25 February 2020Source: The Lancet Diabetes &EndocrinologyAuthor(s): Ida Pernicova, Stephen Kelly, Sharon Ajodha, Anju Sahdev, Jonathan P Bestwick, Plamena Gabrovska, Olufunso Akanle, Ramzi Ajjan, Blerina Kola, Marietta Stadler, William Fraser, Mirjam Christ-Crain, Ashley B Grossman, Costantino Pitzalis, Márta Korbonits
Publication date: Available online 25 February 2020Source: The Lancet Diabetes &EndocrinologyAuthor(s): Martin Reincke
DiabetesMine reports on the impact of two recent diabetes product recalls, on Medtronic and Omnipod insulin pumps.
Publication date: Available online 26 February 2020Source: Current Therapeutic ResearchAuthor(s): Hailemaryam Alemu, Workagegnehu Hailu, Aynshet Adane